Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells

The splicing factor SF3B1 is the most commonly mutated gene in the myelodysplastic syndrome (MDS), particularly in patients with refractory anemia with ring sideroblasts (RARS). We investigated the functional effects of SF3B1 disruption in myeloid cell lines: SF3B1 knockdown resulted in growth inhibition, cell cycle arrest and impaired erythroid differentiation and deregulation of many genes and pathways, including cell cycle regulation and RNA processing. MDS is a disorder of the hematopoietic stem cell and we thus studied the transcriptome of CD34+ cells from MDS patients with SF3B1 mutations using RNA sequencing. Genes significantly differentially expressed at the transcript and/or exon level in SF3B1 mutant compared with wild-type cases include genes that are involved in MDS pathogenesis (ASXL1 and CBL), iron homeostasis and mitochondrial metabolism (ALAS2, ABCB7 and SLC25A37) and RNA splicing/processing (PRPF8 and HNRNPD). Many genes regulated by a DNA damage-induced BRCA1–BCLAF1–SF3B1 protein complex showed differential expression/splicing in SF3B1 mutant cases. This is the first study to determine the target genes of SF3B1 mutation in MDS CD34+ cells. Our data indicate that SF3B1 has a critical role in MDS by affecting the expression and splicing of genes involved in specific cellular processes/pathways, many of which are relevant to the known RARS pathophysiology, suggesting a causal link.

[1]  M. Huynen,et al.  Mutations in the UQCC1-Interacting Protein, UQCC2, Cause Human Complex III Deficiency Associated with Perturbed Cytochrome b Protein Expression , 2013, PLoS genetics.

[2]  M. Cazzola,et al.  Ring sideroblasts and sideroblastic anemias , 2011, Haematologica.

[3]  Michael Heuser,et al.  Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. , 2012, Blood.

[4]  J. Boultwood,et al.  The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes. , 2014, Advances in biological regulation.

[5]  Nam Jin Yoo,et al.  Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors , 2013, International journal of cancer.

[6]  E. Wang,et al.  Global Profiling of Alternative Splicing Events and Gene Expression Regulated by hnRNPH/F , 2012, PloS one.

[7]  Masayuki Yamamoto,et al.  A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation , 2014, International Journal of Hematology.

[8]  R. Moreau,et al.  Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis. , 2013, Journal of hepatology.

[9]  H. Aburatani,et al.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. , 2013, The Journal of clinical investigation.

[10]  Melanie Keppler,et al.  The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress , 2009, Nature.

[11]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[12]  B. Dörken,et al.  Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice , 1996, The Journal of experimental medicine.

[13]  M. Cazzola,et al.  The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts , 2013, Leukemia.

[14]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[15]  J. Valcárcel,et al.  Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.

[16]  David Gentien,et al.  SF3B1 mutations are associated with alternative splicing in uveal melanoma. , 2013, Cancer discovery.

[17]  M. Heuser,et al.  SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications , 2012, Leukemia.

[18]  Luca Malcovati,et al.  The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts , 2008, PloS one.

[19]  A. Jankowska,et al.  SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.

[20]  A. Jankowska,et al.  Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. , 2012, Blood.

[21]  S. Miyano,et al.  Haploinsufficiency of Sf3b1 leads to compromised stem cell function but not to myelodysplasia , 2014, Leukemia.

[22]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[23]  J. Maciejewski,et al.  Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. , 2013, Blood.

[24]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[25]  T. Beilharz,et al.  In vivo mutation of pre‐mRNA processing factor 8 (Prpf8) affects transcript splicing, cell survival and myeloid differentiation , 2013, FEBS letters.

[26]  J. Conboy,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 28, 2013. For personal use only. , 2004 .

[27]  U. Germing,et al.  Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts , 2012, Leukemia.

[28]  N. Hacohen,et al.  RNA interference knockdown of hU2AF35 impairs cell cycle progression and modulates alternative splicing of Cdc25 transcripts. , 2006, Molecular biology of the cell.

[29]  A. Iwama,et al.  Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. , 2014, Blood.

[30]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Huber,et al.  Detecting differential usage of exons from RNA-seq data , 2012, Genome research.

[32]  Seishi Ogawa,et al.  PRPF8 Defects Cause Missplicing in Myeloid Malignancies , 2014, Leukemia.

[33]  M. Cazzola,et al.  Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. , 2003, Blood.

[34]  M. Salto‐Tellez,et al.  Identification of a BRCA1-mRNA Splicing Complex Required for Efficient DNA Repair and Maintenance of Genomic Stability , 2014, Molecular cell.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  S. Jackson,et al.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.

[37]  Peter J Campbell,et al.  Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms , 2011, Blood.

[38]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[39]  Rui Zhang,et al.  Effects of cyclic AMP response element binding protein–Zhangfei (CREBZF) on the unfolded protein response and cell growth are exerted through the tumor suppressor p53 , 2014, Cell cycle.

[40]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[41]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[42]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[43]  A. Brownlie,et al.  Mitoferrin is essential for erythroid iron assimilation , 2006, Nature.

[44]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[45]  J. Barnard,et al.  Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron , 2014, Leukemia.

[46]  A. Jankowska,et al.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.

[47]  M. Cazzola,et al.  Disruption of SF 3 B 1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells , 2015 .